The online forum on "the strategy of strengthening the pharmaceutical industry" was successfully held!

Biomedicine is an important strategic industry related to people's health and national security. Biotechnology innovation has become the main battlefield of competition among major pharmaceutical countries.The "14th Five-Year Plan for the Development of Pharmaceutical Industry" issued in December 2021 clearly puts forward the development goal of innovation-driven transformation. In response to the national biomedical innovation, the online forum on "the strategy of strengthening the pharmaceutical industry-technology, capital and intellectual property rights" was successfully held at 2: 00 p.m. on July 20.

This event is sponsored by Nanjing Jiangbei New District Industrial Technology Research Park and Beijing Peiyou Innovation Pharmaceutical Biotechnology Co., Ltd. Hua Xun. International Intellectual Property and Foreign-related Legal Service Platform, Nanjing Huaxun Intellectual Property Consulting Co., Ltd., Huaxun (Shanghai) Intellectual Property Consulting Co., Ltd., Taiwan Qingchen Law Firm, Jiance Intellectual Property Consulting Nanjing Co., Ltd.

This activity invites four industry experts to discuss and exchange learning together.The strategy of strengthening the pharmaceutical industry--technology,Capital andIntellectual Property,At present, there is still a big gap between the level of biomedical innovation in China and that of developed countries and regions in Europe and the United States, and there are still constraints in terms of system, technology, talents and so on. However, the role of intellectual property as a strategic resource for national development and the core element of international competitiveness has become more prominent. Implement the strategy of strengthening the country with intellectual property rights, comprehensively enhance the comprehensive strength of my country's intellectual property rights, and vigorously stimulate the innovative vitality of technology, capital and intellectual property rights in the whole society, and enhance the country Core competitiveness.

Dr. Qingchen Hou, Chairman of Nanjing Huaxun Intellectual Property Consulting Co., Ltd., analyzed the three interest groups of drug patent issues: patent drug dealers, generic drug dealers, and the drug public, and emphasized thatAny issue involving pharmaceutical patents, especially the issue of industrialization, is closely related to how to coordinate the interests of the above three in policy.From all aspects of compulsory licensing of pharmaceutical patents to analyze, to provide a series of suggestions.

Qingchen Law Firm Intellectual Property Lawyer (Australia) Jian Zhiyang from an overseas perspective, first analyzed the current situation of Australia's pharmaceutical market and.The concept of "new use of old drugs. At the same time, it tells us that when major international pharmaceutical companies go patent layout, many of the first cloth will be cut from Australia. What are the advantages of pharmaceutical companies choosing Australia as their investment: 1. High efficiency, 2. Return on investment, 3. Patent disputes. Lawyer Jane gives advice that "it can be used well and turned into a legal tool.

The third topic,Nanjing Zhihe Pharmaceutical Technology Co., Ltd.Deputy General Manager/Peptide Chief ScientistDr. Ding Wei isEveryone to share-- Changes in domestic pharmaceutical companies under the epidemic. Dr. Ding analyzed the development trend of the pharmaceutical industry under the epidemic, the market environment faced by pharmaceutical enterprises from the policy level, and the thinking of the future changes of pharmaceutical enterprises. It also tells the story of the dawn of Chinese medicine.

At the end of the event, Dr. Shi Kaikai, partner of Enran Venture Capital, showed us the development process of China's innovative drug research and development.The first half of 2022-IPO market review, from the perspective of China and the United States dislocation comparison analysis of the development path of the innovative drug market, bringing the current biopharmaceutical industry's basic judgment-"through the wind and rain, return to normal".

In the intellectual property industry, Huaxun has been providing high-quality and professional comprehensive intellectual property services for enterprises and universities step by step, hoping to contribute to the construction of China's intellectual property power under the leadership of the state and the government.